In clinical trials
Digestive & weight
Petrelintide
Evidence
Clinical trials
Class
Long-acting amylin analog
KEY TAKEAWAY
Petrelintide is a long-acting amylin analog being developed by Zealand Pharma and Roche for weight management. Petrelintide is not FDA-approved and is being tested in clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting amylin analog
Being studied for
Studied for obesity
Key fact
Petrelintide is not FDA-approved and is being tested in clinical trials.
Route
Weekly subcutaneous injection in trials
Evidence strength
Clinical trials
Petrelintide is a long-acting amylin analog being developed by Zealand Pharma and Roche for weight management.
It acts on amylin receptors to increase fullness. Its developers hope it will cause less nausea than GLP-1 drugs.
Petrelintide is not FDA-approved and is being tested in clinical trials.
Studied for obesity.
Early trials reported mainly mild gut-related effects, but data are limited.
Petrelintide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.